All In Biotech

Drug Trial Radar · NCT04555525

A Pilot Study on the Use of Seysara for Rosacea

Last checked: Nov 20, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Apr 15, 2019

Primary completion

Sep 23, 2020

Study completion Oct 1, 2020

Sponsor

Lead sponsor
Derm Research, PLLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)

Conditions

  • Acne Rosacea

Interventions

  • sarecyclineDrug

    sarecycline tablet

  • Centrum Adult MultivitaminDietary supplement

    Centrum Adult Mulltivitamin tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IGA (Investigator Global Assessment)Time frame: 12 weeks
  2. Inflammatory Lesion CountTime frame: Baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Skin Sciences, PLLC

    Louisville, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.